Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma

Annals of Oncology

Volumn 16, Issue 6, 2005, Pages 923-927

  Manegold, C ^a   Symanowski, J ^b   Gatzemeier, U ^c   Reck, M ^c   von Pawel, J ^d   Kortsik, C ^e   Nackaerts, K ^f   Lianes, P ^g   Vogelzang, N J ^h  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b ELI LILLY AND COMPANY   (United States)

^c KRANKENHAUS GROSSHANSDORF   (Germany)

^d ASKLEPIOS FACHKLINIKEN MÜNCHEN GAUTING   (Germany)

^e St Hildegardis Krankenhaus   (Germany)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g HOSPITAL DE MATARÓ   (Spain)

^h NEVADA CANCER INSTITUTE   (United States)

Author keywords

Malignant pleural mesothelioma; Pemetrexed; Second line chemotherapy

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CISPLATIN; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; NAVELBINE; PEMETREXED; PLATINUM DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; PHASE 3 CLINICAL TRIAL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; FEMALE; GLUTAMATES; GUANINE; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 21344471421     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi187     Document Type: Article

References (23)

1. Fizazi K, Doubre H, Le Chevalier T et al. Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study. J Clin Oncol 2003; 21: 349-354.
2. Baas P, Ardizzoni A, Grossi F et al. The activity of raltitrexed (Tomudex®) in malignant pleural mesothelioma. an EORTC phase II study (08992). Eur J Cancer 2003; 39: 353-357.
3. Sorensen PG, Bach F, Bork E, Hansen HH. Randomised trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma. Cancer Treat Rep 1985; 69: 1431-1432.
4. Samson MK, Wasser LP, Borden EC et al. Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study. J Clin Oncol 1987; 5: 86-91.
5. Chahinian AP, Antman K, Goutsou M et al. Randomised phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. J Clin Oncol 1993; 11: 1559-1565.
6. Vogelzang NJ, Taub RN, Shin D et al. Phase III randomized trial of onconase vs doxorubicin in patients with unresectable malignant mesothelioma. Proc Am Soc Clin Oncol 2000; 19: 577a (Abstr 2274).
7. Tomek S, Emri S, Krejcy K, Manegold C. Chemotherapy for malignant pleural mesothelioma: past results and recent developments. Br J Cancer 2003; 88: 167-174.
8. Herndon JE, Green MR, Chahinian AP et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998; 113: 723-731.
9. Sterman DH, Larry R, Kaiser LR, Albelda SM. Advances in the treatment of malignant pleural mesothelioma. Chest 1999; 116: 504-20.
10. Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636-2644.
11. Paoletti P, Pistolesi M, Rusthoven JJ et al. Correlation of pulmonary function tests with best tumor response status: Results from the phase III study of pemetrexed+cisplatin vs. cisplatin in malignant pleural mesothelioma. Proc Am Soc Clin Oncol 2003; 22: 659 (Abstr 2651).
12. Gralla RJ, Hollen PJ, Liepa AM et al. Improving quality of life in patients with malignant pleural mesothelioma: Results of the randomized pemetrexed+cisplatin vs. cisplatin trial using the LCSS-meso instrument. Proc Am Soc Clin Oncol 2003; 22: 621 (Abstr 2496).
13. Giaccone G, O'Brien ME, Byrne MJ et al. Phase II trial of ZD0473 as second-line therapy in mesothelioma. Eur J Cancer 2002; 38 (Suppl 8): S19-S24.
14. Vogelzang NJ. Gemcitabine and cisplatin: Second-line chemotherapy for malignant mesothelioma? J Clin Oncol 1999; 17: 2626-2627.
15. Kindler HL, van Meerbeeck JP. The role of gemcitabine in the treatment of malignant mesothelioma. Semin Oncol 2002; 29: 70-76.
16. Byrne MJ, Davidson JA, Musk AW et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 1999; 17: 25-30.
17. Nowak A, Byrne M, Williamson R. Multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 2002; 87: 491-496.
18. Pavlakis N, Vogelzang NJ. Second-line chemotherapy. In Pass H, Carbone M, Vogelzang N (eds): Malignant Mesothelioma. New York, NY: Springer Verlag. In press 2005.
19. Mbidde EK, Harland SJ, Calvert AH, Smith IE. Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma. Cancer Chemother Pharmacol 1986; 18: 284-285.
20. Raghavan D, Gianoutsos P, Bishop J et al. Phase II trial of carboplatin in the management of malignant mesothelioma. Clin Oncol 1990; 8: 151-154.
21. Vogelzang NJ, Goutsou M, Corson JM et al. Carboplatin in malignant mesothelioma: A phase II study of the Cancer and Leukemia Group B. Cancer Chemother Pharmacol 1990; 27: 239-242.
22. Schutte W, Blankenburg T, Lauerwald K et al. A multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma. Clin Lung Cancer 2003; 4: 294-297.
23. Van Meerbeeck JP, Manegold C, Gaafar R et al. A randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An intergroup study of the EORTC Lung Cancer Group and NCIC. Proc Am Soc Clin Oncol 2004; 22: 6222 (Abstr 7021).